A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
Lee S. Rosen
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Francisco Robert
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Daniela Matei
Research Funding - TRACON Pharma
Jonathan Wade Goldman
Research Funding - TRACON Pharma
David S. Mendelson
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
E. Gabriela Chiorean
Research Funding - TRACON Pharma
Robert Matthew Strother
Research Funding - TRACON Pharma
Ben K. Seon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma
Delia Alvarez
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Michael S. Gordon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - TRACON Pharma